A Global Health Shift: Elevating Fatty Liver Disease to the World Stage
A pivotal editorial in The Lancet Gastroenterology & Hepatology spotlights a major policy development in global non-communicable disease (NCD) strategy. The World Health Organization is set to table a resolution at the May 2026 World Health Assembly to formally include steatotic liver disease (SLD), which encompasses conditions like non-alcoholic fatty liver disease (NAFLD) and its progressive form NASH, within the global NCD definition. This move represents a significant course correction, as the global public health response has historically prioritized cardiovascular diseases, cancers, respiratory diseases, and diabetes, often overlooking the substantial morbidity and mortality burden of liver diseases. The inclusion aims to catalyze coordinated international action, resource allocation, and research focus to combat this growing digestive health challenge.
Study Significance: For gastroenterologists and hepatologists, this formal recognition by the WHO validates the clinical urgency of steatotic liver disease and is likely to reshape public health priorities and funding landscapes. It underscores the need for integrated care models that connect liver health with broader metabolic and cardiovascular management. This development should prompt clinicians and researchers to advocate for and develop improved screening protocols, biomarkers, and context-specific treatment strategies aligned with this elevated global health agenda.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
